Accession Number:



Whole-Body RSI-MRI as an Indicator for Radiation Therapy Response of Metastatic Prostate Cancer

Descriptive Note:

Technical Report,30 Sep 2017,29 Sep 2018

Corporate Author:

University of California San Diego La Jolla United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Prostate cancer is the second leading cause of cancer death in men. New treatment paradigms are entirely dependent on a accurate diagnosis of sites of metastatic disease, and b the ability to accurately characterize response to treatments. We aim to determine if Restriction Spectrum Imaging RSI can improve detection of metastatic disease as well as monitor the effects of therapy targeted to metastatic sites. This is an IRB-approved longitudinal prospective cohort study of men with known metastatic prostate cancer and men who are at high risk of metastatic disease. To date, we have surmounted numerous regulatory hurdles e.g. IRB approval and technical challenges e.g. optimization of the RSI-MRI protocol for whole body imaging. We have successfully recruited multiple patients leading to whole body RSI-MRI scans in 38 men to date. Greater than half of the men who participated were shown to have metastatic disease, several of whom were not known to have metastatic disease prior to RSI-MRI. Accurate depiction of sites of metastases is expected to aid in treatment of patients.

Subject Categories:

  • Medicine and Medical Research
  • Medicine and Medical Research

Distribution Statement: